A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes

Trial Profile

A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 16 Sep 2016 Results assessing the effect of semaglutide on hypoglycaemic counter-regulation, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 25 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top